{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:08:52Z","timestamp":1779466132618,"version":"3.53.1"},"reference-count":21,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,5,5]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pegenzileukin (SAR444245), a pegylated non-alpha recombinant human interleukin (IL)-2 variant, avoids engagement of the IL-2 receptor \u03b1 subunit (IL-2R\u03b1) chain and associated toxicities, while retaining engagement of IL-2R\u03b2\u03b3, for activation of effector T cell and natural killer (NK) cell. The first-in-human study of pegenzileukin with pembrolizumab showed initial efficacy and tolerable safety in advanced and metastatic solid tumors. In this study, we evaluate pegenzileukin with cemiplimab for advanced or metastatic melanoma (MM) and cutaneous squamous cell carcinoma (CSCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 1\/2, open-label, multicenter study evaluated drug combinations in patients with MM (Cohort A) and CSCC (Cohort B). Pegenzileukin was given at two dose levels (16\u2009\u00b5g\/kg: Cohort A1 and B1 and 24\u2009\u00b5g\/kg: Cohort A2 and B2) during dose escalation and recommended phase 2 dose (RP2D) during dose expansion, while cemiplimab was given at a dose of 350\u2009mg; both drugs were administered every 3 weeks as a 30-minute intravenous infusion. The primary endpoint was the objective response rate (ORR); secondary endpoints included dose-limiting toxicities (DLTs), progression-free survival (PFS), safety, and exploratory biomarker endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 46 patients were enrolled. At the RP2D of pegenzileukin (16\u2009\u00b5g\/kg, n=20 in Cohort A1 and n=16 in Cohort B1), the ORR was 40% in Cohort A1 and 56.3% in Cohort B1. In Cohort A1, one patient achieved a complete response, and seven achieved a partial response (PR). In Cohort B1, nine patients achieved a PR. At the RP2D, 75.0% and 85.7% responders, respectively, in Cohort A1 and Cohort B1 had a duration of response of \u226512 months. The PFS rate at 6 months was 55.0% in Cohort A1 and 70.7% in Cohort B1. Five DLTs occurred in four patients: Cohort A had one case of \u22653 Grade thrombocytopenia and one of Grade 2 cytokine release syndrome, while Cohort B had one case of \u22653 Grade alanine transaminase\/aspartate transaminase increases and one infusion-related reaction (IRR). Grade 1 or 2 IRRs were the most common adverse events. Treatment led to robust expansion of NK and CD8 T-cells, without an increase of regulatory T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pegenzileukin in combination with cemiplimab at the RP2D of 16\u2009\u00b5g\/kg showed a manageable safety profile and promising translational data supporting its mechanism of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04913220\">NCT04913220<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014347","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:55:16Z","timestamp":1779465316000},"page":"e014347","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1\/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04913220","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04913220","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Carlos","family":"Rojas","sequence":"first","affiliation":[{"name":"Medical Oncology, Bradford Hill Centro de investigaci\u00f3n en c\u00e1ncer, Santiago, Santiago Metropolitan Region, Chile"},{"name":"Universidad Finis Terrae, Santiago, Santiago Metropolitan Region, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2644-1790","authenticated-orcid":false,"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[{"name":"Service de Dermatologie, CHU Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-8179","authenticated-orcid":false,"given":"John J","family":"Park","sequence":"additional","affiliation":[{"name":"Macquarie Medical School, Macquarie University, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Matamala","sequence":"additional","affiliation":[{"name":"Department of Oncology, Instituto Oncol\u00f3gico Fundaci\u00f3n Arturo L\u00f3pez P\u00e9rez, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9560-4631","authenticated-orcid":false,"given":"Adyb","family":"Baakili","sequence":"additional","affiliation":[{"name":"Sanofi SA Recherche and Developpement, Paris, \u00cele-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Rao","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-1370","authenticated-orcid":false,"given":"Jing","family":"Xu","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7878-4069","authenticated-orcid":false,"given":"Laurent","family":"Andrieu","sequence":"additional","affiliation":[{"name":"Sanofi SA Recherche and Developpement, Paris, \u00cele-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Paehler","sequence":"additional","affiliation":[{"name":"Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Abbadessa","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"},{"name":"Universit\u00e0 degli Studi di Napoli Federico II, Naples, Campania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026052208551298000_14.5.e014347.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126395","article-title":"Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances","volume":"22","author":"Strashilov","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026052208551298000_14.5.e014347.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01854-3","article-title":"Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches","volume":"22","author":"Hasan","year":"2023","journal-title":"Mol Cancer"},{"key":"2026052208551298000_14.5.e014347.3","unstructured":"Society AC . Cancer facts and figures. 2024.1\u201384."},{"key":"2026052208551298000_14.5.e014347.4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026052208551298000_14.5.e014347.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.059"},{"key":"2026052208551298000_14.5.e014347.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra022137"},{"key":"2026052208551298000_14.5.e014347.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"2026052208551298000_14.5.e014347.8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14740338.2022.1993819","article-title":"Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma","volume":"21","author":"Villani","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"2026052208551298000_14.5.e014347.9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026052208551298000_14.5.e014347.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2026052208551298000_14.5.e014347.11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026052208551298000_14.5.e014347.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"2026052208551298000_14.5.e014347.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2026052208551298000_14.5.e014347.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2026052208551298000_14.5.e014347.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nat Commun"},{"key":"2026052208551298000_14.5.e014347.16","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/2767-9764.CRC-24-0278","article-title":"A Precision Engineered Interleukin-2 for Bolstering CD8+ T- and NK-cell Activity without Eosinophilia and Vascular Leak Syndrome in Nonhuman Primates","volume":"4","author":"Ma","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026052208551298000_14.5.e014347.17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1495"},{"key":"2026052208551298000_14.5.e014347.18","doi-asserted-by":"crossref","first-page":"S885","DOI":"10.1016\/j.annonc.2022.07.873","article-title":"747P Phase I study of SAR444245 (SAR\u2019245) as monotherapy (mono) and combined with pembrolizumab (pembro) or cetuximab (cetux) in patients (pts) with advanced solid tumors","volume":"33","author":"Falchook","year":"2022","journal-title":"Ann Oncol"},{"key":"2026052208551298000_14.5.e014347.19","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-LB041","article-title":"Abstract LB041: THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced\/metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1\/2 Study","volume":"81","author":"Janku","year":"2021","journal-title":"Cancer Res"},{"key":"2026052208551298000_14.5.e014347.20","doi-asserted-by":"crossref","unstructured":"Fu Siqing MM , Falchook G , Barve M , et al . Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended Phase 2 dose (RP2D). J Immunother Cancer 2024. doi:10.1136\/jitc-2024-SITC2024.0196","DOI":"10.1136\/jitc-2024-SITC2024.0196"},{"key":"2026052208551298000_14.5.e014347.21","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1510"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:55:18Z","timestamp":1779465318000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,22]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014347"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014347","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}